Medical Updates

DANAMI-2 Trial: Sustained Long-Term Benefits of pPCI over Fibrinolysis in STEMI Patients

A 16-year follow-up of the DANAMI-2 (The DANish Acute Myocardial Infarction 2) trial demonstrated sustained benefits of primary percutaneous...

20 Sep, 2019

Email this page
Preventing Recurrent VTEs in Patients with CVT: Dabigatran vs. Dose-Adjusted Warfarin

The findings of the RE-SPECT CVT (A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral...

16 Sep, 2019

Email this page
Prasugrel vs. Ticagrelor in ACS Patients: Which is Better?

Prasugrel rather than ticagrelor rendered greater protection against a composite of death, myocardial infarction (MI) and stroke at one year in...

11 Sep, 2019

Email this page
Benefits of Alirocumab in Patients with Polyvascular Disease and Recent Acute Coronary Syndrome

The findings of the pre-specified analysis from ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During...

09 Sep, 2019

Email this page

Key Trials

SMART-DATE Trial: Long-Term DAPT-The Standard of Care for ACS Patients Undergoing PCI with DES

The SMART-DATE trial recommends that ACS patients undergoing PCI with DES be treated with prolonged DAPT (at least 12 months) rather than short-term...

Long Term Treatment with Riociguat Sustains Clinical Benefits for upto One Year in CTPH

Long-term treatment with riociguat had a favorable benefit-risk profile in patients with inoperable chronic thromboembolic pulmonary hypertension (...

VERDICT Trial: A Head-to-Head Comparison of Early vs. Standard Care Invasive Strategy in NTSE-ACS Patients

The VERDICT trial compared the long-term clinical outcomes following an early invasive coronary evaluation strategy vs. the standard invasive...

Six Months vs. Twelve Months of DAPT in Event-Free STEMI Patients after Primary PCI with Second Generation DES

The study demonstrated six months of DAPT to be non-superior to 12 months of DAPT in STEMI patients who remain event free after primary PCI with...

Slide Library

Medical Management Strategy of CTEPH: Role of Riociguat

Riociguat, a stimulator of soluble guanylate cyclase, has been globally approved for the treatment of PAH and inoperable CTEPH and persistent/...

Email this page
Macitentan: 1st ERA Proven to Reduce Morbidity and Mortality in PAH

Macitentan is an orally active, potent, tissue targeting ERA that is indicated for the treatment of pulmonary arterial hypertension (PAH). It is the...

Email this page
Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH) is the presence of mean pulmonary artery pressure (mPAP) ≥ 25 mmHg following an episode of...

Email this page
Diabetic Dyslipidemia

Dyslipidemia is one of the key risk factors for cardiovascular disease (CVD) in diabetes mellitus. This slide set provides information on the...

Email this page

Our Publications

Mexohar (Mexiletine) Monograph

About 5% of patients with cardiac arrhythmias or with heart failure are diagnosed with a ventricular tachycardia. Recurrent Ventricular Tachycardia...

Gutron (Midodrine hydrochloride) Monograph

Orthostatic Hypotension is common in elderly (>70 years of age) and can also occur secondary to neuropathy like in diabetes or central lesions...

Azmarda (Sacubitril/Valsartan) FAQs

This booklet on frequently asked questions on sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) provides...

Retefast (Reteplase) Datasheet

This datasheet provides an overview on the pharmacology, clinical efficacy, safety, indications and dosage of reteplase.

Patient Education

Understanding Angioplasty

Angioplasty is a life-saving procedure to open up blocked or narrowed blood vessels. This document gives a brief idea about the procedure.

Understanding Obesity

This document explains what is obesity, what is the impact of obesity on overall health and what are the benefits of weight loss. 


Know more about the risk factors, associated ill-effects and tips for management of hypertension or high blood pressure. 


What percent of your patients who need oral anticoagulation, receive warfarin?
26% (5 votes)
16% (3 votes)
11% (2 votes)
16% (3 votes)
26% (5 votes)
Almost all
5% (1 vote)
Total votes: 19